Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 1
2016 2
2017 2
2018 4
2019 1
2020 2
2021 4
2022 3
2023 2
2024 7
2025 4
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Statistical models for Alzheimer's disease clinical trials: Lessons learned from the DIAN-TU Platform Trial.
Li Y, Wang G, Xiong C, Shan G, Cao Y, Llibre-Guerra J, Hassenstab J, McDade E, Bateman RJ. Li Y, et al. J Alzheimers Dis. 2026 Jun;111(3):1192-1199. doi: 10.1177/13872877261441645. Epub 2026 Apr 13. J Alzheimers Dis. 2026. PMID: 41972916 Free PMC article.
BackgroundAlzheimer's disease (AD) clinical trials often involve uneven follow-up durations and long-term open-label extensions (OLE), yet conventional statistical models are typically designed for fixed schedules, limiting their efficiency in such settings.ObjectiveTo describe a …
BackgroundAlzheimer's disease (AD) clinical trials often involve uneven follow-up durations and long-term open-label extensions (OLE), yet c …
Etalanetug (E2814) in dominantly inherited Alzheimer's disease: an open-label phase 1b/2 study to assess safety and target engagement in participants with mild to moderate cognitive impairment.
Andreozzi E, Yagi T, Wildsmith K, Rawal S, Horie K, Boyd P, Takahashi E, Barthélemy NR, Aluri J, Charil A, Reilhac A, Gordon BA, Flores S, Verbel D, Sauter N, Benzinger TLS, McDade E, Mummery C; Dominantly Inherited Alzheimer Network (DIAN); Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU); Zhou J, Bateman RJ, Reyderman L. Andreozzi E, et al. Alzheimers Res Ther. 2026 Apr 10;18(1):87. doi: 10.1186/s13195-026-02047-y. Alzheimers Res Ther. 2026. PMID: 41964075 Free PMC article. Clinical Trial.
Treating Alzheimer's disease in a person living with HIV.
Clifford DB, Benzinger TLS, Han JY, Powles S, Paczynski M, Ances BM, Campbell JW. Clifford DB, et al. Alzheimers Dement (Amst). 2026 Feb 17;18(1):e70259. doi: 10.1002/dad2.70259. eCollection 2026 Jan-Mar. Alzheimers Dement (Amst). 2026. PMID: 41717085 Free PMC article.
The landscape of autosomal-dominant Alzheimer's disease: global distribution and age of onset.
Liu H, Marsh TW, Shi X, Renton AE, Bowling KM, Ziegemeier E, Wang G, Cao Y, Aristel A, Li J, Dickson A, Perrin RJ, Goate AM, Fernández V, Day GS, Doering M, Daniels A, Gordon BA, Benzinger TLS, Hassenstab J, Ibanez L, Supnet-Bell C, Xiong C, Allegri R, Berman SB, Fox NC, Ryan NS, Huey ED, Vöglein J, Noble JM, Roh JH, Jucker M, Laske C, Ikeuchi T, Sanchez-Valle R, Schofield PR, Mendez PC, Chhatwal JP, Farlow M, Lee JH, Levey AI, Levin J, Lopera F, Martins R, Niimi Y, Rosa-Neto P, Morris JC, Bateman RJ, Karch CM, Cruchaga C, McDade E, Llibre-Guerra JJ. Liu H, et al. Brain. 2025 Jul 7;148(7):2429-2440. doi: 10.1093/brain/awaf038. Brain. 2025. PMID: 39903689 Free PMC article.
A total of 550 variants in the APP, PSEN1 and PSEN2 genes were identified, of which 279 were classified as pathogenic or likely pathogenic based on American College of Medical Genetics and Genomics and the Association for Molecular Pathology criteria, utilizing data from the D …
A total of 550 variants in the APP, PSEN1 and PSEN2 genes were identified, of which 279 were classified as pathogenic or likely pathogenic b …
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.
Bateman RJ, Li Y, McDade EM, Llibre-Guerra JJ, Clifford DB, Atri A, Mills SL, Santacruz AM, Wang G, Supnet C, Benzinger TLS, Gordon BA, Ibanez L, Klein G, Baudler M, Doody RS, Delmar P, Kerchner GA, Bittner T, Wojtowicz J, Bonni A, Fontoura P, Hofmann C, Kulic L, Hassenstab J, Aschenbrenner AJ, Perrin RJ, Cruchaga C, Renton AE, Xiong C, Goate AA, Morris JC, Holtzman DM, Snider BJ, Mummery C, Brooks WS, Wallon D, Berman SB, Roberson E, Masters CL, Galasko DR, Jayadev S, Sanchez-Valle R, Pariente J, Kinsella J, van Dyck CH, Gauthier S, Hsiung GR, Masellis M, Dubois B, Honig LS, Jack CR, Daniels A, Aguillón D, Allegri R, Chhatwal J, Day G, Fox NC, Huey E, Ikeuchi T, Jucker M, Lee JH, Levey AI, Levin J, Lopera F, Roh J, Rosa-Neto P, Schofield PR; Dominantly Inherited Alzheimer's Disease–Trials Unit. Bateman RJ, et al. Lancet Neurol. 2025 Apr;24(4):316-330. doi: 10.1016/S1474-4422(25)00024-9. Lancet Neurol. 2025. PMID: 40120616 Free PMC article. Clinical Trial.
BACKGROUND: Amyloid plaque removal by monoclonal antibody therapies slows clinical progression in symptomatic Alzheimer's disease; however, the potential for delaying the onset of clinical symptoms in asymptomatic people is unknown. The Dominantly Inherited Alzhe …
BACKGROUND: Amyloid plaque removal by monoclonal antibody therapies slows clinical progression in symptomatic Alzheimer's disease; however, …
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial.
Bateman RJ, Li Y, McDade EM, Llibre-Guerra JJ, Clifford DB, Atri A, Mills SL, Santacruz AM, Wang G, Supnet C, Benzinger TLS, Gordon BA, Ibanez L, Klein G, Baudler M, Doody RS, Delmar P, Kerchner GA, Bittner T, Wojtowicz J, Bonni A, Fontoura P, Hofmann C, Kulic L, Hassenstab J, Aschenbrenner AJ, Perrin RJ, Cruchaga C, Renton AE, Xiong C, Goate AA, Morris JC, Holtzman DM, Snider BJ, Mummery C, Brooks WS, Wallon D, Berman SB, Roberson E, Masters CL, Galasko DR, Jayadev S, Sanchez-Valle R, Pariente J, Kinsella J, van Dyck CH, Gauthier S, Robin Hsiung GY, Masellis M, Dubois B, Honig LS, Jack CR, Daniels A, Aguillón D, Allegri R, Chhatwal J, Day G, Fox N, Huey E, Ikeuchi T, Jucker M, Lee JH, Levey AI, Levin J, Lopera F, Roh J, Rosa-Neto P, Schofield PR; Dominantly Inherited Alzheimer’s Disease-Trials Unit. Bateman RJ, et al. medRxiv [Preprint]. 2025 Jan 29:2024.10.29.24316289. doi: 10.1101/2024.10.29.24316289. medRxiv. 2025. Update in: Lancet Neurol. 2025 Apr;24(4):316-330. doi: 10.1016/S1474-4422(25)00024-9. PMID: 39974075 Free PMC article. Updated. Preprint.
BACKGROUND: Amyloid-plaque removal by monoclonal antibody therapies slows clinical progression in symptomatic Alzheimer's disease; however, the potential for delaying the onset of clinical symptoms in asymptomatic people is unknown. The Dominantly Inherited Alzhe …
BACKGROUND: Amyloid-plaque removal by monoclonal antibody therapies slows clinical progression in symptomatic Alzheimer's disease; however, …
Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagement.
Rentz DM, Aisen PS, Atri A, Hitchcock J, Irizarry M, Landen J, Matthews BR, Miller DS, Mahinrad S, Napoli S, Okhravi HR, Petersen RC, Siemers ER, Weber CJ, Weisman DC, Carrillo MC. Rentz DM, et al. Alzheimers Dement. 2024 Nov;20(11):8162-8171. doi: 10.1002/alz.14199. Epub 2024 Sep 22. Alzheimers Dement. 2024. PMID: 39306695 Free PMC article.
36 results